ABT-737

目錄號: HY-50907 純度: 99.96%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

ABT-737 是一種 BH3 模擬物，是一種有效的 Bcl-2、Bcl-x_L 和 Bcl-w 抑制劑，EC₅₀ 分別為 30.3 nM、78.7 nM 和 197.8 nM。ABT-737 誘導(dǎo) BCL-2/BAX 復(fù)合物的破壞和 BAK 依賴性但不依賴 BIM 的內(nèi)在凋亡途徑激活。ABT-737 誘導(dǎo)自噬，并且具有用于急性髓系白血病 (AML) 研究的潛力。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

ABT-737 Chemical Structure

CAS No. : 852808-04-9

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥805	In-stock
5 mg	￥750	In-stock
10 mg	￥900	In-stock
50 mg	￥3000	In-stock
100 mg	￥5300	In-stock
200 mg	現(xiàn)貨	詢價
500 mg		詢價
1 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of ABT-737:

ABT-737-d₈ In-stock

MCE 顧客使用本產(chǎn)品發(fā)表的 47 篇科研文獻(xiàn)

•Cancer Cell. 2023 Jul 10;41(7):1242-1260.e6. [Abstract]
•Cell. 2022 Sep 1;185(18):3356-3374.e22. [Abstract]
•Cell Mol Immunol. 2021 May;18(5):1186-1196. [Abstract]
•Cell Rep Med. 2024 May 29:101592. [Abstract]
•Nat Commun. 2023 Sep 19;14(1):5709.
•Adv Sci (Weinh). 2023 Jul 19;e2207108. [Abstract]

•Cell Death Differ. 2022 Jun 20. [Abstract]
•Haematologica. 2017 Apr;102(4):755-764. [Abstract]
•Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2207280119. [Abstract]
•Cell Death Dis. 2020 Nov 15;11(11):982. [Abstract]
•Cancer Lett. 2019 Oct 1;461:102-111. [Abstract]
•Cell Rep. 2024 Dec 21;44(1):115094. [Abstract]
•Cell Rep. 2024 May 15;43(5):114237. [Abstract]
•Cell Death Discov. 2024 Jan 15;10(1):29. [Abstract]
•Cell Rep. 2023 Mar 17;42(3):112278. [Abstract]
•Cell Rep. 2021 May 11;35(6):109102. [Abstract]
•J Cell Mol Med. 2025 Jan;29(1):e70331. [Abstract]
•Toxicology. 2024 Aug 6:153906. [Abstract]
•Am J Cancer Res. 2024 May 15;14(5):2584-2607. [Abstract]
•Chem Biol Interact. 2024 Mar 1:391:110898. [Abstract]
•Exp Neurol. 2023 Oct 29:371:114590. [Abstract]
•J Cell Mol Med. 2022 Dec 15. [Abstract]
•Pharmaceutics. 2022 Jun 6;14(6):1209. [Abstract]
•Pharmaceutics. 2019 May 27;11(5):247. [Abstract]
•Eur J Pharm Sci. 2018 May 31;121:243-250. [Abstract]
•ACS Med Chem Lett. 2015 Jun 22;6(8):948-52. [Abstract]
•Clin Transl Sci. 2024 Sep;17(9):e70030. [Abstract]
•Theriogenology. 2024 Sep 24:230:285-298. [Abstract]
•Phytochemistry. 2024 Jun 28:114197. [Abstract]
•Immunopharmacol Immunotoxicol. 2023 Jul 7;1-10. [Abstract]
•J Phys Chem A. 2023 Apr 6. [Abstract]
•Biol Chem. 2023 Feb 14. [Abstract]
•Int J Biochem Cell Biol. 2023 Feb;155:106359. [Abstract]
•In Vitro Cell Dev Biol Anim. 2022 Sep 19. [Abstract]
•Biochem Biophys Res Commun. 18 August 2022.
•Biochem Biophys Res Commun. 2022 Jun 18;609:93-99. [Abstract]
•J Ovarian Res. 2016 Apr 14;9(1):25. [Abstract]
•Norges teknisk-naturvitenskapelige universitet. 2024.
•bioRxiv. 2024 Jul 30:2024.07.29.605645. [Abstract]
•Research Square Preprint. 2023 Oct 6.
•Research Square Preprint. 2023 Oct 9.
•bioRxiv. 2023 Sep 7.
•Research Square Preprint. 2023 Jul 7.
•Graduate School of Medical Sciences, University of Groningen. 2020 Jan.
•Mathematics and System Programming Lomonosov Moscow State University. 2019 Jul.
•bioRxiv. September 11, 2018.
•Harvard Medical School LINCS LIBRARY

: ABT-737 purchased from MCE. Usage Cited in: Cancer Lett. 2019 Oct 1;461:102-111. [Abstract]; Expression of active (cleaved) PARP and active (cleaved) Caspase-3 after 48h of treatment with AGS, 1 μM ABT-737 or 1 μM ABT-737 added to AGS as determined by Western blot. Floating cells are included in lysate.

ABT-737 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Bcl-2 Family 亞型特異性產(chǎn)品:

查看所有亞型

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

生物活性
實(shí)驗(yàn)參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research^[1]^[2]^[3].

IC₅₀ & Target^[1]

Bcl-2

30.3 nM (EC₅₀)

Bcl-xL

78.7 nM (EC₅₀)

Bcl-W

197.8 nM (EC₅₀)

Bcl-B

1820 nM (EC₅₀)

Bfl-1

>10 μM (EC₅₀)

Mcl-1

>10 μM (EC₅₀)

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	0.74 μM Compound: 1, ABT-737	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
DU-145	IC₅₀	27.6 μM Compound: 7, ABT-737	Cytotoxicity against human DU145 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human DU145 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
FL5.12	EC₅₀	30 nM Compound: 1, ABT-737	Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum	[PMID: 18841882]
FL5.12	EC₅₀	7.7 nM Compound: 1, ABT-737	Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum	[PMID: 18841882]
HCT-116	IC₅₀	4.06 μM Compound: 7, ABT-737	Cytotoxicity against human HCT116 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HCT116 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HCT-116	IC₅₀	47.7 μM Compound: ABT-737	Cytotoxicity against human HCT116 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay	[PMID: 22172701]
HL-60	IC₅₀	0.76 μM Compound: 1, ABT-737	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.97 μM Compound: ABT-737	Growth inhibition of human HL60 cells after 72 hrs by MTT assay Growth inhibition of human HL60 cells after 72 hrs by MTT assay	[PMID: 27712939]
Jurkat	IC₅₀	1.38 μM Compound: 7, ABT-737	Cytotoxicity against human Jurkat cells after 48 hrs by cell titer-blue assay Cytotoxicity against human Jurkat cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
K562	IC₅₀	16.4 μM Compound: ABT-737	Induction of apoptosis in Mcl1 dependent human K562 cells after 48 hrs by Annexin V staining based flow cytometry Induction of apoptosis in Mcl1 dependent human K562 cells after 48 hrs by Annexin V staining based flow cytometry	[PMID: 23314054]
K562	IC₅₀	34.7 μM Compound: 1, ABT-737	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
Leukemia cell	IC₅₀	> 1 μM Compound: 1, ABT-737	Binding affinity to human/mouse chimeric Mcl-1 by luminescence proximity assay Binding affinity to human/mouse chimeric Mcl-1 by luminescence proximity assay	[PMID: 23767404]
Leukemia cell	IC₅₀	> 10 μM Compound: 1, ABT-737	Binding affinity to human/mouse chimeric Mcl-1 by surface plasmon resonance assay Binding affinity to human/mouse chimeric Mcl-1 by surface plasmon resonance assay	[PMID: 23767404]
MCF7	IC₅₀	21.26 μM Compound: 7, ABT-737	Cytotoxicity against human MCF7 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human MCF7 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
MCF7	IC₅₀	25.33 μM Compound: ABT-737	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 27712939]
MCF7	EC₅₀	4.39 μM Compound: ABT-737	Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35421577]
MDA-MB-435	IC₅₀	> 122.94 μM Compound: ABT-737	Cytotoxicity against human MDA-MB-435 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay	[PMID: 22172701]
MEF	EC₅₀	> 10000 nM Compound: 1, ABT-737	Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 1% serum Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 1% serum	[PMID: 21366295]
MEF	EC₅₀	> 10000 nM Compound: 1, ABT-737	Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 10% serum Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 10% serum	[PMID: 21366295]
MEF	EC₅₀	0.013 μM Compound: 1; ABT-737	Cytotoxicity against MCL deficient mouse embryonic fibroblast cells assessed as reduction in cell viability in presence of 1 % fetal calf serum measured after 24 hrs by propidium iodide staining based flow cytometric analysis Cytotoxicity against MCL deficient mouse embryonic fibroblast cells assessed as reduction in cell viability in presence of 1 % fetal calf serum measured after 24 hrs by propidium iodide staining based flow cytometric analysis	[PMID: 33904752]
MEF	EC₅₀	2.03 nM Compound: 1, ABT-737	Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 1% serum Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 1% serum	[PMID: 21366295]
MEF	EC₅₀	51 nM Compound: 1, ABT-737	Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum	[PMID: 21366295]
MEF	EC₅₀	51 nM Compound: 1, ABT-737	Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% serum Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% serum	[PMID: 21366295]
MOLT-4	IC₅₀	227 nM Compound: ABT-263	Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
NCI-H1417	IC₅₀	0.13 μM Compound: 1, ABT-737	Growth inhibition of human NCI-H1417 cells after 4 days by WST8 assay Growth inhibition of human NCI-H1417 cells after 4 days by WST8 assay	[PMID: 22448988]
NCI-H1417	IC₅₀	173.4 nM Compound: 1, ABT-737	Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay	[PMID: 23448298]
NCI-H1417	IC₅₀	412 nM Compound: 1, ABT-737	Antiproliferative activity against human NCI-H1417 cells after 4 days by WST8 assay Antiproliferative activity against human NCI-H1417 cells after 4 days by WST8 assay	[PMID: 22747598]
NCI-H146	EC₅₀	0.087 μM Compound: 1, ABT-737	Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum	[PMID: 18841882]
NCI-H146	IC₅₀	0.097 μM Compound: 1, ABT-737	Growth inhibition of human NCI-H146 cells after 4 days by WST8 assay Growth inhibition of human NCI-H146 cells after 4 days by WST8 assay	[PMID: 22448988]
NCI-H146	IC₅₀	37 nM Compound: 1, ABT-737	Antiproliferative activity against human NCI-H146 cells after 4 days by WST8 assay Antiproliferative activity against human NCI-H146 cells after 4 days by WST8 assay	[PMID: 22747598]
NCI-H146	IC₅₀	43.8 nM Compound: ABT-263	Antiproliferative activity against human NCI-H146 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Antiproliferative activity against human NCI-H146 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
NCI-H187	IC₅₀	137.7 nM Compound: 1, ABT-737	Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay	[PMID: 23448298]
NCI-H1963	IC₅₀	54 nM Compound: 1, ABT-737	Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay	[PMID: 23448298]
NCI-H1963	IC₅₀	59 nM Compound: 1, ABT-737	Antiproliferative activity against human NCI-H1963 cells after 4 days by WST8 assay Antiproliferative activity against human NCI-H1963 cells after 4 days by WST8 assay	[PMID: 22747598]
NCI-H23	IC₅₀	71.16 μM Compound: ABT-737	Growth inhibition of human NCI-H23 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H23 cells after 72 hrs by MTT assay	[PMID: 27712939]
NCI-H460	IC₅₀	8.03 μM Compound: 7, ABT-737	Cytotoxicity against human H460 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human H460 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
Platelet	IC₅₀	242 nM Compound: ABT-263	Toxicity in human platelet assessed as reduction in cell viability measured after 48 hrs by MTS assay Toxicity in human platelet assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
Raji	IC₅₀	93.49 μM Compound: ABT-737	Cytotoxicity against human Raji cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay Cytotoxicity against human Raji cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay	[PMID: 22172701]
RS4-11	IC₅₀	0.27 μM Compound: ABT-737	Induction of apoptosis in Bcl2 dependent human RS4:11 cells after 48 hrs by Annexin V staining based flow cytometry Induction of apoptosis in Bcl2 dependent human RS4:11 cells after 48 hrs by Annexin V staining based flow cytometry	[PMID: 23314054]
RS4-11	IC₅₀	0.33 μM Compound: ABT-737	Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29453135]
RS4-11	IC₅₀	49 nM Compound: ABT-263	Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
SK-OV-3	IC₅₀	46.59 μM Compound: ABT-737	Growth inhibition of human SKOV3 cells after 72 hrs by MTT assay Growth inhibition of human SKOV3 cells after 72 hrs by MTT assay	[PMID: 27712939]
SU.86.86	IC₅₀	4.24 μM Compound: 7, ABT-737	Cytotoxicity against human SU-8686 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human SU-8686 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
U-266	IC₅₀	27.35 μM Compound: ABT-737	Growth inhibition of human U266 cells after 72 hrs by MTT assay Growth inhibition of human U266 cells after 72 hrs by MTT assay	[PMID: 27712939]

體外研究
(In Vitro)

ABT-737 與 BCL-2、BCL-X_L 和 BCL-W 具有高親和力 (K_i<1 nM)，但與其他抗凋亡 BCL-2 家族成員（包括 MCL-1 和 BFL-1）的結(jié)合力較弱 (K_i>460 nM)。ABT-737 與 BCL-X_L 和 BCL-2 的 BH3 結(jié)合槽結(jié)合^[1]。
ABT-737（100 nM；1-72 小時）誘導(dǎo) HL-60 細(xì)胞凋亡并與化療產(chǎn)生協(xié)同作用^[1]。
ABT-737（5、7.5、10 μM；72 小時）導(dǎo)致約 80% 的 HCT116 細(xì)胞死亡。BAX 敲除變體對 ABT-737 具有完全抗性^[1]。
ABT-737 對細(xì)胞周期分布沒有影響。ABT-737 破壞 BCL-2/BAX 異二聚化并誘導(dǎo) HL-60 白血病細(xì)胞中的 BAX 構(gòu)象變化^[1]。
ABT-737 可誘導(dǎo)敏感細(xì)胞中 BAX/BAK 依賴性最大 O₂ 消耗率受損。MCF10A 細(xì)胞中穩(wěn)定的 BCL-2 過表達(dá)可誘導(dǎo) ABT-737 敏感的死亡狀態(tài)。ABT-737 可誘導(dǎo) B 細(xì)胞淋巴瘤細(xì)胞中劑量依賴性最大 O₂ 消耗率受損^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

ABT-737（20、30 mg/kg/天；腹腔注射；持續(xù) 21 天）在 20 和 30 mg/kg 劑量水平下分別可抑制 4 至 6 周齡 CB.17 Scid 小鼠（患有人類白血病 KG-1 細(xì)胞）的白血病負(fù)擔(dān) 48% 和 53%^[1]。
ABT-737 顯著延長了這種惡性白血病模型中小鼠的生存期^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

813.43

Formula

C₄₂H₄₅ClN₆O₅S₂

CAS 號

852808-04-9

性狀

固體

顏色

Yellow to orange

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 66.67 mg/mL (81.96 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	1.2294 mL	6.1468 mL	12.2936 mL
5 mM	0.2459 mL	1.2294 mL	2.4587 mL
10 mM	0.1229 mL	0.6147 mL	1.2294 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請?jiān)?年內(nèi)使用， -20°C儲存時，請?jiān)?年內(nèi)使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實(shí)驗(yàn)：

請根據(jù)您的實(shí)驗(yàn)動物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (3.07 mM); 懸濁液; 超聲助溶

此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.07 mM); 懸濁液; 超聲助溶

此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.07 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個月以上的動物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。
方案四

請依序添加每種溶劑： 2% DMSO 40% PEG300 5% Tween-80 53% Saline
Solubility: 2 mg/mL (2.46 mM); 懸濁液; 超聲助溶

動物溶解方案計算器

請輸入動物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.96%

選擇批次：

Data Sheet (656 KB) SDS (393 KB)

COA (194 KB) HNMR (324 KB) LCMS (256 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov;10(5):375-88. [Content Brief]

[2]. Ahamed Saleem, et al. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate. 2012 Sep 1;72(12):1374-81. [Content Brief]

[3]. Clerc P, et al. Polster BM.Rapid Detection of an ABT-737-Sensitive Primed for Death State in Cells Using Microplate-Based Respirometry.PLoS One. 2012;7(8):e42487. Epub 2012 Aug 3. [Content Brief]

Kinase Assay ^[1]	To determine the binding affinity of GST-BCL-2 family proteins to the FITC-conjugated BH3 domain of BIM (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR), FPAs are performed as follows. Briefly, 100 nM of GST-BCL-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-BIM BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. IC₅₀s are determined using GraphPad Prism software. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[3]	Cells are treated with ABT-737, ABT-263, or vehicle (DMSO) for 4 h in XF24 assay medium (6×10⁴?MCF10A cells, see medium composition below) or RPMI 1640 medium (1×10⁶?B-cell lymphoma cells) and apoptosis is analyzed by Annexin-V-binding/PI exclusion or by sub-diploid nuclei determination. FACS analysis is performed on Becton Dickinson FACScan or FACScalibur instruments. Data analysis is performed with CellQuest software. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	For intraperitoneal (i.p.) administration, 1 g/mL?stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4?5; final concentration of DMSO ≤ 1%). Mice injected with FD/ΔRaf-1:ER cells are treated with either ABT-737 (20 and 30 mg/kg/mouse every day i.p. for 21 days starting on day 1 post-cell injection (n=9-10 mice per group) or vehicle or left untreated (control); mice injected with human KG-1 cells are treated with 30 mg/kg ABT-737 starting on day 18 post-cell injection. For noninvasive imaging of FD/ΔRaf-1:ER-luc?cells, anesthetized mice are injected with 150 mg/kg of D-luciferin and placed for imaging in the In Vivo Imaging System with total imaging time of 2 min. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov;10(5):375-88. [Content Brief] [2]. Ahamed Saleem, et al. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate. 2012 Sep 1;72(12):1374-81. [Content Brief] [3]. Clerc P, et al. Polster BM.Rapid Detection of an ABT-737-Sensitive Primed for Death State in Cells Using Microplate-Based Respirometry.PLoS One. 2012;7(8):e42487. Epub 2012 Aug 3. [Content Brief]

ABT-737 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2294 mL	6.1468 mL	12.2936 mL	30.7341 mL
	5 mM	0.2459 mL	1.2294 mL	2.4587 mL	6.1468 mL
	10 mM	0.1229 mL	0.6147 mL	1.2294 mL	3.0734 mL
	15 mM	0.0820 mL	0.4098 mL	0.8196 mL	2.0489 mL
	20 mM	0.0615 mL	0.3073 mL	0.6147 mL	1.5367 mL
	25 mM	0.0492 mL	0.2459 mL	0.4917 mL	1.2294 mL
	30 mM	0.0410 mL	0.2049 mL	0.4098 mL	1.0245 mL
	40 mM	0.0307 mL	0.1537 mL	0.3073 mL	0.7684 mL
	50 mM	0.0246 mL	0.1229 mL	0.2459 mL	0.6147 mL
	60 mM	0.0205 mL	0.1024 mL	0.2049 mL	0.5122 mL
	80 mM	0.0154 mL	0.0768 mL	0.1537 mL	0.3842 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ABT-737852808-04-9ABT737ABT 737Bcl-2 FamilyApoptosisAutophagyMitophagyMitochondrial AutophagyBH3mimeticBCL-2/BAXBIMAMLHL-60HCT116Inhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ABT-737

Customer Review

Other Forms of ABT-737:

MCE 顧客使用本產(chǎn)品發(fā)表的 47 篇科研文獻(xiàn)

ABT-737 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Bcl-2 Family 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計算器

稀釋計算器

ABT-737 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ABT-737

Customer Review

Other Forms of ABT-737:

ABT-737 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 47 篇科研文獻(xiàn)

ABT-737 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Bcl-2 Family 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

ABT-737 相關(guān)抗體:

摩爾計算器

稀釋計算器

ABT-737 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z